

**FAX TRANSMITTAL
TO THE UNITED STATES PATENT OFFICE**

**RECEIVED
CENTRAL FAX CENTER**

SEP 02 2004

Applicants Docket Number:
DEA2002/0044US NP

Applicants:
Schafer, et al.

Serial No.
10/607,521

Filing Date:
June 26, 2003

Title of Invention:
2003 Use of Vasopeptidase Inhibitors in the Treatment of Metabolic Diseases, Nephropathy and Advanced Glycation End-Product Associated Diseases

CERTIFICATE OF TRANSMISSION
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at **703-872-9306**, on
Date of Deposit **September 2, 2004**
Printed Name of Person Signing Certificate **Bonnie Stein**
Signature *Bonnie Stein*

**Total Number of Pages Sent, 17
including FAX cover:**

Attorney: **Lawrence Martin**

Group Art **1614**

Unit:

Examiner: **Raymond J. Henley III**
Nephropathy and Advanced

TO: Mail Stop
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

☒ Amendment, 37 CFR 1.121© and Reply, 37
CFR 1.111 – 16 pgs.

☐ Charge deposit account, in duplicate

☐ Extension of Time Petition

☐ Issue Fee Transmittal & Advance Order

☐ Maintenance Fee Transmittal

☐ Fee Transmittal

☐ Petition under 37 CFR ____

☐ Other ____

☐ Other ____

Receipt Confirmed:

Signed _____

Dated _____

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. www.aventis.com
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)